Brought to you by 
MeiraGTx acquires AAV gene therapy company Vector Neurosciences for up to $24mm
14 Sep 2020
Executive Summary
MeiraGTx Holdings PLC acquired privately held fellow gene therapy biotech Vector Neurosciences Inc. in an all-stock transaction, issuing a total of 225k Class A ordinary shares (valued at $3mm) to Vector’s stockholders.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MeiraGTx acquires AAV gene therapy company Vector Neurosciences for up to $24mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice